Home > About Primary Immunodeficiency (PI) > Treatment

Treating PI With Immunoglobulin (Ig) Infusion

Ig treatment is one option for treating primary immunodeficiency (PI) that is caused by impaired antibody production. However, it is not appropriate for everyone. Talk to your doctor about what treatment may be best for you.

What Is Ig?

Ig—also referred to as IgG, immune globulin, and immunoglobulin—is one type of antibody normally made by the body's immune system. Others include IgM, IgE, IgD and IgA. The IgG antibodies help fight off bacteria and viruses that cause infections that can make you sick. If you have PI, your body may not be making enough antibodies, or some of the antibodies it's making don't work properly.1 That's why you get sick so often.

I was excited to have a plan to get better.

Sue, medical professional with PI

What Is Ig Treatment?

Ig treatment temporarily replaces some of the antibodies that your body isn't making on its own or that don't work properly.1 The goal of this treatment is to keep enough antibodies in your blood so your body can help to fight off bacteria and viruses, and help keep you from getting sick so often.1

Where Ig Treatment Comes From

Human plasma donations are the first step in producing Ig treatments. A donor's plasma is put through a rigorous series of tests, including screening for specific infectious diseases and measurement of protein levels and hematocrit to make sure they are both in an acceptable range for donation. Once it is determined safe for use, the plasma is sent to a processing plant where it is processed into numerous plasma based treatments, including Ig treatment.1

Learn more about Shire's Immunoglobulin (Ig) treatment options.

Reference: 1. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013.

    

  • Sign up to get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Enroll Now
  • 
  • Ask an Advocate Questions about PI or PI treatments? Our trained Patient and Nurse Advocates can help, and asking your question is easy with our Ask An Advocate feature.
    Start Getting Answers

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.

-----

Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.


© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.

Selected Important Safety Information for GAMMAGARD LIQUID
  • GAMMAGARD LIQUID can cause decreased kidney function or kidney failure, blood clots in the heart, brain, lungs or elsewhere in the body. Call your healthcare professional or go to your emergency department right away if you have: Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem. Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.
  • Do not take GAMMAGARD LIQUID if you have a known history of a severe allergic reaction to IgG or other blood products.